Hence, studies of the Fmr1 KO rodent model have illuminated a variety of molecular mechanisms relevant to FXS, especially those pertinent to the regulation of protein synthesis, and may provide biological targets for therapeutic intervention [24], complementing ongoing clinical trials in human FXS patients [151, 152]. Here, FMR1 is linked to fragile X syndrome.